Hong Kong · Delayed Price · Currency is HKD Lepu Biopharma Company Description
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drug candidates in anti-tumor targeted therapy and oncology immunotherapy in China and internationally.
The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of MSI-H/dMMR solid tumors solid tumors and melanoma.
It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; CMG901 CLDN18.2-targeted ADC, which is in phase III trials for treating gastric and gastroesophageal junction carcinoma and other solid tumors; and MRG004A TF-targeted ADC, which is in phase III clinical trial for treating pancreatic ductal adenocarcinoma.
In addition, the company is developing CG00705 Oncolytic virus for treating bacillus calmette-guerin unresponsive non-muscle invasive bladder cancer; and MRG002, which is in phase III trials to treat breast cancer, as well as HER2-positive.
Further, the company is developing MRG001 CD20-targeted ADC for treating non-Hodgkin’s lymphoma; MRG006A, MRG007, and CTM012 for the treatment of solid tumors.
Lepu Biopharma Co., Ltd. was incorporated in 2018 and is headquartered in Shanghai, China. Lepu Biopharma Co., Ltd. operates as a subsidiary of Ningbo Houde Yimin Information Technology Co., Ltd.
| Country | China |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 710 |
| CEO | Ziye Sui |
Contact Details
Address: Block 4 Shanghai, 201612 China | |
| Phone | 86 21 6768 0899 |
| Website | lepubiopharma.com |
Stock Details
| Ticker Symbol | 2157 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100004SM4 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ziye Sui M.D., Ph.D. | GM, Chief Executive Officer and Executive Director |
| Dr. Zhongjie Pu | Executive Chairman |
| Yunyi Li | Chief Financial Officer and Joint Company Secretary |
| Lixuan Zhao | Employee Representative Supervisor and Investor Relations Director |
| Siu Kuen Lai FCIS, FCS | Joint Company Secretary |